Keywords: ضد EGFR; Head & neck cancer; Recurrent; Metastatic; Chemotherapy; Anti-EGFR; Second line;
مقالات ISI ضد EGFR (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ضد EGFR; Anti-EGFR; Efficacy; Monoclonal antibody; Safety; Targeted therapy;
Keywords: ضد EGFR; Metastatic colorectal cancer; Primary tumour location; Sidedness; Prognostic biomarker; Predictive biomarker; Cetuximab; Panitumumab; Bevacizumab; Anti-EGFR; Anti-VEGF;
Keywords: ضد EGFR; Predictive Markers; Prognostic Markers; Colorectal Cancer; Molecular Subtypes; RAS; BRAF; MSI; DNA Mismatch Repair; Immunotherapy; Targeted Therapy; Biologics; Anti-EGFR; Anti-VEGF; CCS; colon cancer subtypes; CIMP; CpG island methylator phenotype; CIN; c
Keywords: ضد EGFR; Urothelial carcinoma; Immunotherapy; FGFR targeted therapies; Targeting PI3K/AKT/mTOR pathway; Anti-angiogenesis; Anti-EGFR; Cell cycle;
L'accompagnement d'un patient sous anticancéreux présentant une éruption acnéiforme
Keywords: ضد EGFR; anti-EGFR; cancer; chimiothérapie; dermocosmétique; éruption acnéiforme; thérapie ciblée;
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease
Keywords: ضد EGFR; mCRC; KRAS mutation; PI3KCA mutation; FIr-B/FOx; Anti-VEGF; Anti-EGFR;
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy
Keywords: ضد EGFR; Anal cancer; Immunotherapy; Nivolumab; Anti-EGFR; Cetuximab; Pembrolizumab; Panitumumab;
Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial
Keywords: ضد EGFR; Head and neck cancer; Recurrent/metastatic; Anti-EGFR; Second line treatment; Progression-free survival; Gene expression signatures; Hypoxia signature; Microenvironment score; miRNA; EGFR; epidermal growth factor receptor; mAb; monoclonal antibody; RM; re
Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study
Keywords: ضد EGFR; Anti-EGFR; Biomarker; Chemotherapy; Prognosis; Real-world;
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design
Keywords: ضد EGFR; Anti-EGFR; Clinical trial; Maintenance; Non comparative; Oxaliplatin;
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
Keywords: ضد EGFR; Anti-angiogenesis; Anti-EGFR; Clinical trial; Overall survival; VEGF;
Original ResearchAdvanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. AÂ retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
Keywords: ضد EGFR; Chordoma; Molecular targeted therapy; Imatinib; Antiangiogenics; Anti-EGFR; Prognostic factors;
Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence
Keywords: ضد EGFR; Head and neck; Squamous cell carcinoma; Radiotherapy; Cetuximab; Chemoradiation; Targeted therapy; Anti-EGFR
ReviewUnderstanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer
Keywords: ضد EGFR; Metastatic colorectal cancer; First-line; FOLFOXIRI; Bevacizumab; Anti-EGFR;
Traitements médicaux des cholangiocarcinomes en 2015
Keywords: ضد EGFR; Antiangiogéniques; Anti-EGFR; Cancer des voies biliaires; Chimiothérapie; Cholangiocarcinome; Thérapies ciblées; Antiangiogenics; Anti-EGFR; Biliary tract carcinoma; Chemotherapy; Cholangiocarcinoma; Targeted therapies;
The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011
Keywords: ضد EGFR; Anti-EGFR; Monoclonal antibody; Genotyping; KRAS mutation; Colorectal cancer;
Toxicité cutanée des anti-EGFR (epidermal growth factor receptor) : algorithme thérapeutique du groupe français PROCUR
Keywords: ضد EGFR; anti-EGFR; effets secondaires cutanés; algorithme thérapeutique; EGFR-inhibitors; cutaneous adverse drug reactions; therapeutic algorithm;
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation
Keywords: ضد EGFR; Anti-EGFR; Biomarkers; Colorectal cancer; Resistance
Prise en charge des toxicités des thérapies ciblées en oncologie thoracique
Keywords: ضد EGFR; Toxicité; Thérapies ciblées; Anti-VEGF; Anti-EGFR; Folliculite; HTA; Protéinurie; Saignement; Thrombose; Terrains à risque; Toxicity Anti-VEGF Targeted therapies Anti-EGFR Folliculitis Proteinuria Hypertension Bleeding Thrombosis-risk land;
Emerging therapies for urothelial cancer
Keywords: ضد EGFR; Anti-EGFR; Bladder cancer; Emerging treatments; Eribulin; mTOR inhibition; Nab-paclitaxel; PARP; Sorafenib; Sunitinib; Volasertib
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Keywords: ضد EGFR; Anti-EGFR; Biomarker; Colorectal cancer; KRAS; PIK3CA mutations; PTEN
Laser immunotherapy with gold nanorods causes selective killing of tumour cells
Keywords: ضد EGFR; AuNRs; gold nanorods; anti-EGFR; epidermal growth factor receptor antibody; anti-EGFR-AuNRs; epidermal growth factor receptor antibody conjugated with gold nanorods; A431; human squamous carcinoma cells; PBS; phosphate buffered saline; FITC; fluorescein
Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives
Keywords: ضد EGFR; Metastatic breast cancer; Endocrine treatment; Aromatase inhibitors; Chemotherapy; Anthracyclines; Taxanes; Anti-ErbB2 targeted therapy; Anti-angiogenesis; PARP inhibitors; Anti-EGFR; Bisphosphonates; Anti-RANKL; Palliation; Survival
Effets cutanés des nouvelles molécules utilisées en cancérologie
Keywords: ضد EGFR; Inhibiteurs de tyrosines kinases; Anti-EGFR; Anti-angiogéniques; Folliculite; Effets secondaires cutanésTyrosine kinase inhibitors; Anti-EGFR; Anti-angiogenic therapy; Folliculitis; Skin toxicity